Comparative Pharmacology
Head-to-head clinical analysis: OXALIPLATIN versus TEPYLUTE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OXALIPLATIN versus TEPYLUTE.
OXALIPLATIN vs TEPYLUTE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Oxaliplatin is a platinum-based alkylating agent that forms inter- and intrastrand DNA crosslinks, inhibiting DNA replication and transcription, leading to cell death.
Progestin that transforms endometrium from proliferative to secretory phase, inhibits gonadotropin secretion, and increases cervical mucus viscosity.
85 mg/m² intravenously over 2 hours every 2 weeks in combination with 5-fluorouracil and leucovorin (FOLFOX regimen).
100 mg orally once daily
None Documented
None Documented
Terminal elimination half-life is approximately 40-50 hours for ultrafilterable platinum (active species) and 240-500 hours for total platinum (bound to plasma proteins and erythrocytes). The prolonged half-life reflects slow release from tissue binding.
Clinical Note
moderateOxaliplatin + Digoxin
"Oxaliplatin may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateOxaliplatin + Digitoxin
"Oxaliplatin may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateOxaliplatin + Deslanoside
"Oxaliplatin may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateOxaliplatin + Acetyldigitoxin
"Oxaliplatin may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal elimination half-life is 4-6 hours in healthy adults; prolonged to 10-15 hours in severe renal impairment.
Renal excretion accounts for approximately 50% of the administered platinum, with the remainder eliminated via biliary/fecal routes. Platinum accumulates in erythrocytes and is slowly cleared.
Primarily renal (70-80% unchanged) and fecal (15-20% as metabolites).
Category D/X
Category C
Alkylating Agent
Alkylating Agent